Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

AQSTBullishCorporate Developmentsnews

High materiality8/10

Aquestive advances Anaphylm NDA resubmission to FDA in 2026 catalyst

Aug 11, 2026, 4:25 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Key NDA resubmission catalyst with optional expedited FDA review; potential upside if timelines hold and US launch advances; downside risk from FDA feedback or delays persists.

AI summary

What happened, with direct paths to the underlying reporting

Aquestive reports Q2 2026 results and progress on Anaphylm NDA resubmission in Q3 2026 after human factors and PK validation. The company also targets Canada by year-end 2026 and the EU in early 2027, with an allergist-first launch if approved, signaling near-term regulatory catalysts and upside potential for AQST.

Anaphylm NDA resubmission to FDA planned for Q3 2026; CRL issues addressed.
Completed human factors validation and PK study; primary endpoints met.
Ex-US filings planned: Canada by end-2026; EU by Q1 2027.
Investor call scheduled for August 12, 2026 at 8:00 a.m. ET.
Q2 2026 revenue rose 38% to $13.8M; net loss $22.9M; cash $98.5M.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Aquestive advances Anaphylm NDA resubmission to FDA in 2026 catalyst

AQST Announces Positive Anaphylm Study Findings Supporting Regulatory Pathway

What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment?

US FDA declines to approve Aquestive's oral drug for allergic reactions

Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application